Home » Newsletters » BioWorld Science

BioWorld Science

June 14, 2001

View Archived Issues

Phase III comparative trial of PEG-Intron and Intron A for CML completed

Cephalon signs marketing and distribution agreement for Actiq in Australia and New Zealand

deCODE Genetics and Genmab enter RA alliance

New asthma therapy advances to clinical trials at Kyowa Hakko

Codevelopment agreement reached by Meiji Seika and Solvay for new PD agent

Adenovirus-mediated BMP-2 gene transfer effective in bone defect model

GlaxoSmithKline characterizes SAR for new series of NNRTIs

New biotechnology company formed -- Biovitrum

Intellivax receives funding from Technology Partnerships Canada for Proteosomes

NDA for Plenaxis denied FDA approval

Biomarkers for detecting amyloid aggregates in brain

Canadian launch announced for meningitis conjugate vaccine

AUA news: FimCH vaccine protects against challenge with invasive pyelonephritic E. coli

Xenova gains license to Viron's antiinflammatory protein

In vivo efficacy proven for Genmab's HuMax-EGFr

Intranasal apomorphine now in phase II testing in both male and female sexual dysfunction

Phase I evaluation of CAT-213 begins

Promising results emerge from Tularik-ChemoCentryx drug discovery initiative

Oral desmopressin may have role in nocturia according to AUA presentations

Ivax set to begin phase II study of GYKI-16084 for BPH

Broad-spectrum antibacterial agents from GSK act on FabH

Inhibitors of cathepsin S and/or L and their use described by AstraZeneca researchers

Hydroxamic acid-based inhibitors of sCD23 formation claimed in recent patent

High response rate and rapid and sustained responsiveness reported for Cialis in ED

Yamanouchi presents stable, orally active PDE4 inhibitors

Microcide and Cetek to discover new antimicrobials

New series of telomerase inhibitors identified by Kyowa Hakko

PDE4 inhibitors prepared at Byk Gulden may have therapeutic application in inflammation or ED